Last close As at 05/08/2026
—
— 0.00 (0.00%)
Market capitalisation
—
Research: Healthcare
BioLargo reported record revenue in 2018 of $1.4m, more than doubling from the previous year, with the majority of this revenue attributable to Odor-No-More at $1.1m. Odor-No-More continues to improve its margins and is expected to break even by the end of 2019. Moreover, it expects to provide the data needed to complete a 510(k) for its Clyra wound care product in six months, with a spin-off planned for around the end of 2019, and for the Advanced Oxidation System (AOS) to be commercially available in late 2019 or early 2020 and eventually operating independently.
Written by
BioLargo |
Guidance: Odor-No-More break-even by YE19
Healthcare & industrial services |
Spotlight – QuickView
4 April 2019 |
Share price graph
Share details
Business description
Bull
Bear
Analyst
Edison profile page BioLargo is a research client of Edison Investment Research Limited |
||||||||||||||||||||||||||
BioLargo reported record revenue in 2018 of $1.4m, more than doubling from the previous year, with the majority of this revenue attributable to Odor-No-More at $1.1m. Odor-No-More continues to improve its margins and is expected to break even by the end of 2019. Moreover, it expects to provide the data needed to complete a 510(k) for its Clyra wound care product in six months, with a spin-off planned for around the end of 2019, and for the Advanced Oxidation System (AOS) to be commercially available in late 2019 or early 2020 and eventually operating independently.
Margins improving for Odor-No-More
Odor-No-More continues to be loss-making (gross margin of $552,000 and net loss of $433,000 for 2018), although the investment in increased sales staff is showing early signs that this is translating into an improved bottom line, and in Q418, the unit’s operational loss was reduced to $51,000. CupriDyne Clean was recently integrated into the purchasing system for its fourth national account, and BioLargo has guided to break-even by the end of 2019. The company has also announced a strategic initiative to target the product to the cannabis industry, and has established an undisclosed distributer agreement in the space.
Clyra animal data due with FDA in six months
In December 2018, Clyra completed its transaction with Scion Solutions for intellectual property to its SkinDisc stem cell therapy technology. Clyra is independently financed and the goal is to acquire a portfolio of wound care products and to operate as an independent company around the end of 2019. The FDA has provided guidance on the market clearance pathway for the company’s iodine based antimicrobial product. The company is preparing to initiate a large animal study to support a 510(k) application, and it expects to be able to provide the needed information to the FDA within six months.
AOS enters additional pilot projects
The AOS product developed by BioLargo Water is currently being deployed in a number of pilot projects and is largely financed via grants. The first pilots are being placed in a poultry processing facility in Alberta and a microbrewery in California. Additionally the company is negotiating a pilot program for the processing of storm water in California in accordance with a recent initiative to provide $300m for this purpose in Los Angeles. These projects have shifted resources away from the petrochemical waste water pilot in Tianjin, where funding has not been secured. Per guidance, AOS is targeting commercialization in late 2019 or early 2020.
|
Historical financials
Source: BioLargo reports |
|
|||||||||||
Research: Energy & Resources
With the Aoka Mizu FPSO now on station and hooked up at the Lancaster field, early production system (EPS) first oil remains on track for the end of H119. Hurricane (HUR) is currently focusing on topside commissioning prior to start up, which will be followed by a ramp-up period to a targeted gross plateau rate of 20kbd. In addition to progressing Lancaster, the company has a full programme of activity in its neighbouring Greater Warwick Area (GWA), with a three-well E&A programme expected to kick off in Q219 at Warwick Deep. This accelerated GWA programme is being made possible by Hurricane’s 2018 farm-out to Spirit Energy. Our risked valuation stands at 102.3p/share (from 102.8p/share) as we remove Edison’s 5% capex cost contingency, roll forward NAV and adjust our short-term oil price assumptions (long-term Brent remains $70/bbl).